Clinical trial
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00027690 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00027690 |
|---|---|
| Title | Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer |
| Official title | A Phase II Trial of ZD 1839 (IRESSA) (NSC #715055) in the Treatment of Persistent or Recurrent Endometrial Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Corpus Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Gefitinib, Laboratory Biomarker Analysis |
| Enrollment | 56 |
| Start date | Jun 1, 2002 |
| Primary completion | Sep 1, 2004 |
| Completion | Jul 1, 2013 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: